A Phase 3 interventional study of Everolimus and Tacrolimus in Kidney Transplantation and Renal Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 27 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-01.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing tacrolimus in Graft vs Host Disease — 3 open to participants now, 4 under way, none of them phase 3. Tacrolimus · Graft vs Host Disease.
Among the 36 studies testing tacrolimus in Graft vs Host Disease, this one has the largest enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2012, is one of 2 in phase 3, and was the 28th registered.
804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.
Browse Graft vs Host Disease studies →3 of the 36 studies testing tacrolimus in Graft vs Host Disease are open now, in 1 country. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18–75
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages up to 26
City of Hope Medical Center · Sites in United States
Ages 18–80
By country, each count listing its studies:
Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 28 · Phase 3 4 · Phase 4 3
First in 2000; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 612 is above the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.
Median enrollment 34 across the 32 interventional studies. Of the 32 that completed or were terminated, 15 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
12 studies in Graft vs Host Disease by Novartis: 2 open now, 4 under way, none of them phase 3. Of 8 finished, 7 (88%) have results posted.
Among the 12 studies in Graft vs Host Disease by Novartis, this one has the largest enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2012, is one of 3 in phase 3, and was the 2nd registered.
Novartis’s Graft vs Host Disease studies by the year they started, since 2012.
1 of the studies testing tacrolimus in Graft vs Host Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05621759NYU Langone HealthCyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD | 2027-01-30 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing tacrolimus in Graft vs Host Disease, from their registry updates:
Among Novartis’s 12 in Graft vs Host Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was designed to evaluate the renal function comparing Certican based immunosuppressive regimens with two different CNIs (Tacrolimus or Cyclosporin A) versus a standard treatment with Mycophenolic Acid and Tacrolimus in de novo renal transplant recipients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
--Multi-organ recipients
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tacrolimus · Drug: Enteric Coated Mycophenolate Sodium (EC-MPS) · Drug: Mycophenolate mofetil (MMF) · Drug: Corticosteroids · Drug: Simulect
Drug: Everolimus · Drug: Tacrolimus · Drug: Corticosteroids · Drug: Simulect
Drug: Everolimus · Drug: Cyclosporin A · Drug: Corticosteroids · Drug: Simulect
Also known as: Certican
Capsules: 0.5 mg, 1 mg or 5 mg. Dosing schedule: transplant to month 2: 4-8ng/ml, month 3 to month 12 3-5 ng/ml according to standard blood levels
Capsules: 10 mg, 25 mg, 50 mg or 100 mg. Transplantation to month 2: 75 - 125 ng/ml, month 3 to month 12: 50 - 100 ng/ml
Tablets: 180 mg or 360 mg. Dosing: duration of study 360 mg bid and no less than 360 mg daily dose
Capsules: 250 or 500 mg. Dosing: duration of study 500 mg bid and no less than 500 mg total daily dose
A minimum dose of 5 mg prednisolon or equivalent
Lyophilisate in vials with ampoules of sterile water for injection (5 mL), one vial containing 20 mg lyophilisate given intravenously on the day of transplantation and on day four post-transplantation.
Also known as: Basiliximab
Glomular Filtration Rate (GFR) mL/Min Via Nankivell Method at Month 12 - Standard Regimen vs Certican Regimens
To demonstrate non-inferiority in renal function assessed by glomerular filtration rate (Nankivell formula) in at least one of the Certican® treatment regimens compared to the standard regimen group at month 12 post-transplantation in renal transplant patients. Nankivell formula: GFR = 6.7/Scr + BW/4 - Surea/2 - 100/(height)² + C where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kg, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The eGFR is expressed in mL/min per 1.73m². If a patient was on dialysis at the time of urea or creatinine assessment, the eGFR was set to 0. Analysis set = per protocol set
Time frame: One year post transplant
Percentage of Participants With Composite Treatment Failure Endpoints - Difference Between Groups at Month 12
Combined endpoint included: biopsy proven acute rejection (BPAR) defined as a rejection which was acute and proven by biopsy, graft loss (GL) defined as: allograft was presumed to be lost on the day the patient starts dialysis and not able to be removed from dialysis or death. Patients who prematurely discontinued the study: if the patient did not suffer from an event before discontinuation and reason was not related to efficacy, the patient was assessed as having had no event, otherwise the patient was assessed as having had an event. Full analysis set (FAS)
Time frame: Month 12 post transplant
Glomular Filtration Rate (GFR) Via Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Method at Month 12 Post Transplant
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method = GFR=141 x min(Scr/κ, 1)α x max(Scr/κ, 1)1.209 x 0.993Age x 1.018 \[if female\] x 1.159 \[if black\] where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is 0.329 for females and 0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1. last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model
Time frame: Month 12 post transplant
Glomular Filtration Rate (GFR) mL/Min Via Cockcroft- Gault Method at Month 12 Post Transplant
Cockcroft-Gault formula: For men: GFR= ((140-age) × body weight in kg)∕(72 x serum creatinine in mg∕dl)For women: GFR= (0.85×(140-age) × body weight in kg)∕(72 x serum creatinine in mg/dl), ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model
Time frame: Month 12 post transplant
Glomular Filtration Rate (GFR) Via Modification of Diet in Renal Disease (MDRD) Method at Month 12 Post Transplant
Modification of Diet in Renal Disease (MDRD) = For men: GFR = 170 x (serum creatinine -0,999) x (age-0,176) x (urea nitrogen -0,17) x (albumin0,318) For women: GFR = 170 x (serum creatinine -0,999) x (age-0,176) x (urea nitrogen -0,17) x albumin0,318) x 0.762 with urea nitrogen = urea / 2.144. last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model
Time frame: Month 12 post transplant
Percentage of Participants With Treatment Failure Endpoints at Month 12
Treatment failure endpoints: biopsy proven acute rejection (BPAR) defined as a rejection which was acute and proven by biopsy, graft loss (GL) defined as: allograft was presumed to be lost on the day the patient starts dialysis and not able to be removed from dialysis or death. Patients who prematurely discontinued the study: if the patient did not suffer from an event before discontinuation and reason was not related to efficacy, the patient was assessed as having had no event, otherwise the patient was assessed as having had an event. Full analysis set (FAS)
Time frame: Month 12 post transplant
Percent of Participants With Delayed Graft Function and Slow Graft Function
Delayed graft function (DGF) was defined as the need for dialysis within the first 7 days post-transplantation, excluding the first post-transplantation day. Slow graft function (SGF) was defined as a serum creatinine \>3.0 mg/dL at Day 5 post-transplantation. Full analysis set
Time frame: Post transplant to month 12
Percent of Participants With Delayed Graft Function by Day
Delayed graft function (DGF) was defined as the need for dialysis within the first 7 days post-transplantation, excluding the first post-transplantation day.
Time frame: Post transplant up to day 7
Percent of Participants With Viral Infections
Viral infections for BKV Virus Humane Polyomavirus 1 and Cytomegalovirus
Time frame: Post transplant to month 12
Percent of Participants With Wound Healing Complications During Study
Information collected to report wound healing process which included percentage of participants with complications, fluid collections detected and occurrence of lymphoceles
Time frame: Post transplant until individual reporting
Duration of Wound Healing
A wound will be considered healed if all the suture material and staples are removed and the wound is intact. Number of participants is based on all patients of the respective treatment group in the safety set, excluding patients with no answer (unknown).
Time frame: Post transplant until individual reporting
| Milestone | TAC+MPA | TAC+Certican | CycA+Certican |
|---|---|---|---|
| Started | 205 | 208 | 199 |
| Safety analysis set (sas) | 204 | 210 | 198 |
| Full analysis set (fas) | 205 | 208 | 199 |
| Per protocol set (pps) | 147 | 111 | 80 |
| Completed | 182 | 168 | 158 |
| Not completed | 23 | 40 | 41 |
| Withdrew: Withdrawal by subject | 4 | 16 | 18 |
| Withdrew: Lost to follow-up | 5 | 4 | 2 |
| Withdrew: Death | 5 | 3 | 4 |
| Withdrew: Graft loss/retransplantation | 5 | 8 | 11 |
| Withdrew: Various reasons | 4 | 9 | 6 |
To demonstrate non-inferiority in renal function assessed by glomerular filtration rate (Nankivell formula) in at least one of the Certican® treatment regimens compared to the standard regimen group at month 12 post-transplantation in renal transplant patients. Nankivell formula: GFR = 6.7/Scr + BW/4 - Surea/2 - 100/(height)² + C where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kg, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The eGFR is expressed in mL/min per 1.73m². If a patient was on dialysis at the time of urea or creatinine assessment, the eGFR was set to 0. Analysis set = per protocol set
| mL/min per 1.73m² | TAC+MPA | TAC+Certican | CycA+Certican |
|---|---|---|---|
| Month 1 - Day 1 to 60 (146,111,78) | 62.62 ± 16.931 | 60.54 ± 17.310 | 59.47 ± 16.754 |
| Month 3 - Day 61 to 136 (143,108,79) | 66.36 ± 16.672 | 61.21 ± 14.771 | 62.22 ± 16.196 |
| Month 6 - Day 137 to 228 (142,108,76) | 68.05 ± 16.994 | 62.76 ± 16.763 | 63.17 ± 16.789 |
| Month 9 - Day 229 to 319 (140,106,77) | 69.47 ± 16.251 | 64.68 ± 15.507 | 62.89 ± 14.947 |
| Month12 - Day 320 to 450 (147,111, 80) | 70.41 ± 16.514 | 63.34 ± 16.986 | 61.51 ± 16.942 |
Combined endpoint included: biopsy proven acute rejection (BPAR) defined as a rejection which was acute and proven by biopsy, graft loss (GL) defined as: allograft was presumed to be lost on the day the patient starts dialysis and not able to be removed from dialysis or death. Patients who prematurely discontinued the study: if the patient did not suffer from an event before discontinuation and reason was not related to efficacy, the patient was assessed as having had no event, otherwise the patient was assessed as having had an event. Full analysis set (FAS)
| Percentage of participants | TAC+MPA | TAC+Certican | CycA+Certican | Tac+Certican - Tac+MPA - Difference Between Groups | CycA+Certican -Tac+MPA - Difference Between Groups |
|---|---|---|---|---|---|
| BPAR or graft loss or death | 9.8 | 13.0 | 24.6 | 3.2 | 14.9 |
| BPAR, graft loss, death, or loss of follow-up | 15.6 | 22.6 | 32.7 | 7.0 | 17.1 |
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method = GFR=141 x min(Scr/κ, 1)α x max(Scr/κ, 1)1.209 x 0.993Age x 1.018 \[if female\] x 1.159 \[if black\] where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is 0.329 for females and 0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1. last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model
| mL/min per 1.73m² | TAC+MPA | TAC+Certican | CycA+Certican |
|---|---|---|---|
| Glomular Filtration Rate (GFR) Via Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Method at Month 12 Post Transplant | 51.62 (48.10 to 55.14) | 44.42 (40.95 to 47.89) | 42.44 (38.89 to 45.99) |
Cockcroft-Gault formula: For men: GFR= ((140-age) × body weight in kg)∕(72 x serum creatinine in mg∕dl)For women: GFR= (0.85×(140-age) × body weight in kg)∕(72 x serum creatinine in mg/dl), ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model
| mL/min per 1.73m² | TAC+MPA | TAC+Certican | CycA+Certican |
|---|---|---|---|
| Glomular Filtration Rate (GFR) mL/Min Via Cockcroft- Gault Method at Month 12 Post Transplant | 60.26 (55.85 to 64.68) | 52.25 (47.88 to 56.61) | 51.30 (46.85 to 55.74) |
Modification of Diet in Renal Disease (MDRD) = For men: GFR = 170 x (serum creatinine -0,999) x (age-0,176) x (urea nitrogen -0,17) x (albumin0,318) For women: GFR = 170 x (serum creatinine -0,999) x (age-0,176) x (urea nitrogen -0,17) x albumin0,318) x 0.762 with urea nitrogen = urea / 2.144. last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model
| mL/min per 1.73m² | TAC+MPA | TAC+Certican | CycA+Certican |
|---|---|---|---|
| Glomular Filtration Rate (GFR) Via Modification of Diet in Renal Disease (MDRD) Method at Month 12 Post Transplant | 53.24 (49.62 to 56.87) | 45.72 (42.11 to 49.32) | 43.47 (39.75 to 47.20) |
Treatment failure endpoints: biopsy proven acute rejection (BPAR) defined as a rejection which was acute and proven by biopsy, graft loss (GL) defined as: allograft was presumed to be lost on the day the patient starts dialysis and not able to be removed from dialysis or death. Patients who prematurely discontinued the study: if the patient did not suffer from an event before discontinuation and reason was not related to efficacy, the patient was assessed as having had no event, otherwise the patient was assessed as having had an event. Full analysis set (FAS)
| Percentage of participants | TAC+MPA | TAC+Certican | CycA+Certican |
|---|---|---|---|
| Biopsy proven acute rejection (BPAR) | 9.3 | 12.0 | 24.6 |
| Treated BPAR (tBPAR) | 8.8 | 11.5 | 23.6 |
| Graft loss | 5.4 | 6.3 | 9.0 |
| Death | 4.9 | 6.3 | 6.5 |
Delayed graft function (DGF) was defined as the need for dialysis within the first 7 days post-transplantation, excluding the first post-transplantation day. Slow graft function (SGF) was defined as a serum creatinine \>3.0 mg/dL at Day 5 post-transplantation. Full analysis set
| Percent of participants | TAC+MPA | TAC+Certican | CycA+Certican |
|---|---|---|---|
| Delayed graft function (197,187,172) | 17.8 | 20.3 | 22.1 |
| Slow graft function (195,187,171) | 46.2 | 48.7 | 49.7 |
Delayed graft function (DGF) was defined as the need for dialysis within the first 7 days post-transplantation, excluding the first post-transplantation day.
| Percent of participants | TAC+MPA | TAC+Certican | CycA+Certican |
|---|---|---|---|
| day 1 (8,7,4) | 22.9 | 18.4 | 10.5 |
| day 2 (2,2,2) | 5.7 | 5.3 | 5.3 |
| day 3 (5,1,2) | 14.3 | 2.6 | 5.3 |
| day 4 (4,2,4) | 11.4 | 5.3 | 10.5 |
| day 5 (4,5,3) | 11.4 | 13.2 | 7.9 |
| day 6 (1,1,2) | 2.9 | 2.6 | 5.3 |
| day 7 (2,4,0) | 5.7 | 10.5 | 0.0 |
| >7 days (9,16,21) | 25.7 | 42.1 | 55.3 |
Viral infections for BKV Virus Humane Polyomavirus 1 and Cytomegalovirus
| Percent of participants | TAC+MPA | TAC+Certican | CycA+Certican |
|---|---|---|---|
| Viral infections - CMVMissing | 1.0 | 0.0 | 1.0 |
| Viral infections - CMVAsymptomatic | 7.0 | 1.0 | 1.0 |
| Viral infections - CMVMild | 5.0 | 2.0 | 1.0 |
| Viral infections - CMVModerate | 6.0 | 1.0 | 1.0 |
| Viral infections - CMVSevere | 1.0 | 0.0 | 0.0 |
| Viral infections - BKVAsymptomatic | 10.0 | 8.0 | 5.0 |
| Viral infections - BKVMild | 5.0 | 7.0 | 3.0 |
| Viral infections - BKVModerate | 7.0 | 2.0 | 1.0 |
| Viral infections - BKVSevere | 0 | 0 | 0 |
Information collected to report wound healing process which included percentage of participants with complications, fluid collections detected and occurrence of lymphoceles
| Percent of participants | TAC+MPA | TAC+Certican | CycA+Certican |
|---|---|---|---|
| Wound healing complication | 14.3 | 19.1 | 22.2 |
| Fluids detected | 18.7 | 26.8 | 27.8 |
| Occurrence of lymphoceles | 11.8 | 18.2 | 21.8 |
A wound will be considered healed if all the suture material and staples are removed and the wound is intact. Number of participants is based on all patients of the respective treatment group in the safety set, excluding patients with no answer (unknown).
| days | TAC+MPA | TAC+Certican | CycA+Certican |
|---|---|---|---|
| Duration of Wound Healing | 42.4 ± 41.13 | 54.1 ± 61.97 | 85.3 ± 62.7 |
Collected over Timeframe for AE. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tac+MPA | — | 135/204 (66.2%) | 200/204 (98%) |
| Tac+Certican | — | 161/210 (76.7%) | 205/210 (97.6%) |
| CycA+Certican | — | 144/198 (72.7%) | 196/198 (99%) |
| Event | Tac+MPA | Tac+Certican | CycA+Certican |
|---|---|---|---|
| Urinary tract infectionInfections and infestations | 21/204 | 27/210 | 16/198 |
| LymphoceleVascular disorders | 12/204 | 19/210 | 24/198 |
| Kidney transplant rejectionImmune system disorders | 8/204 | 19/210 | 22/198 |
| Complications of transplanted kidneyInjury, poisoning and procedural complications | 18/204 | 22/210 | 18/198 |
| Blood creatinine increasedInvestigations | 11/204 | 20/210 | 19/198 |
| Transplant rejectionImmune system disorders | 8/204 | 5/210 | 17/198 |
| Acute kidney injuryRenal and urinary disorders | 9/204 | 12/210 | 7/198 |
| Renal transplant failureImmune system disorders | 8/204 | 9/210 | 11/198 |
| Cytomegalovirus infectionInfections and infestations | 11/204 | 2/210 | 2/198 |
| PyelonephritisInfections and infestations | 10/204 | 9/210 | 8/198 |
| Event | Tac+MPA | Tac+Certican | CycA+Certican |
|---|---|---|---|
| Oedema peripheralGeneral disorders | 62/204 | 82/210 | 99/198 |
| ConstipationGastrointestinal disorders | 71/204 | 69/210 | 81/198 |
| Urinary tract infectionInfections and infestations | 81/204 | 74/210 | 72/198 |
| Wound complicationInjury, poisoning and procedural complications | 68/204 | 64/210 | 56/198 |
| HyperkalaemiaMetabolism and nutrition disorders | 65/204 | 53/210 | 58/198 |
| HypertensionVascular disorders | 52/204 | 62/210 | 57/198 |
| AnaemiaBlood and lymphatic system disorders | 44/204 | 53/210 | 58/198 |
| Diarrhoea infectiousInfections and infestations | 56/204 | 40/210 | 29/198 |
| NauseaGastrointestinal disorders | 46/204 | 44/210 | 42/198 |
| BK virus infectionInfections and infestations | 45/204 | 36/210 | 18/198 |
Full analysis set consisted of all randomized patients who received at least one dose of study drug
| Age, Continuous(years) | TAC+MPA | TAC+Certican | CycA+Certican | Total |
|---|---|---|---|---|
| Mean | 55.3 ± 12.09 | 54.3 ± 13.50 | 55.1 ± 12.61 | 54.9 ± 12.74 |
| Sex: Female, Male(Participants) | TAC+MPA | TAC+Certican | CycA+Certican | Total |
|---|---|---|---|---|
| Female | 65 | 70 | 66 | 201 |
| Male | 140 | 138 | 133 | 411 |
Ran from Dec 2012 to primary completion in Mar 2016, 38 months.
Results were first posted in May 2017, 1 year 1 month after primary completion.
Of 31 phase 3 interventional studies under Graft vs Host Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 48. This study's 38 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Everolimus · Tacrolimus · Cyclosporine